WHO ICTRP trial
A Phase 1, Open-label, Single-dose, Randomized, Crossover Study to Assess the…
NL-OMON49835 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON49835 |
|---|---|
| Public title | A Phase 1, Open-label, Single-dose, Randomized, Crossover Study to Assess the Local Tolerability of the Tildrakizumab 200 mg Dose when Delivered as Single Subcutaneous Injection via the 200 mg/2 mL Pre-filled Syringe |
| Scientific title | A Phase 1, Open-label, Single-dose, Randomized, Crossover Study to Assess the Local Tolerability of the Tildrakizumab 200 mg Dose when Delivered as Single Subcutaneous Injection via the 200 mg/2 mL Pre-filled Syringe - Tolerability Study with Tildrakizumab 200 mg Dose |
| Primary sponsor | Almirall |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | The Netherlands |
| Conditions | Psoriasis;10014982;Psoriasis |
| Interventions | The volunteer receives 200 mg of tildrakizumab twice. Tildrakizumab is given once as 1 injection and once as 2 injections. The test substance will be administered under the skin (subcutaneously) in the volunteer's arm, thigh, or abdomen… |
| Registration date | Aug 18, 2020 |
| Target size | 42 |
| Secondary IDs | 2020-000183-37;NL73105.056.20 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: